$34.5m market cap

$0.17 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and ClyraGuard, a disinfectant for healthcare workers. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

Share price graph
Price performance
Actual (15.3) 21.8 (32.9)
Relative* (20.2) 3.4 (42.8)
52-week high/low US$0.4/US$0.1
*% relative to local index
Key management
Dennis Calvert President & CEO